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Abstract
Increasing antimicrobial resistance and limited alternative treatments have led to fluoroquinolone- resistant Shigella strain 
inclusion on the WHO global priority pathogens list. In this study we characterized multiple Shigella isolates from Malawi with 
whole genome sequence analysis, identifying the acquirable fluoroquinolone resistance determinant qnrS1.
DATA SUMMARY
The authors confirm all supporting data, code and protocols 
have been provided within the article or through supple-
mentary data files. The raw sequencing reads from the eight 
Shigella and Escherichia coli isolates which were subjected 
to whole genome sequencing have been deposited in the 
National Center for Biotechnology Information (NCBI) 
Short Read Archive under accession numbers: ERR2525592, 
ERR2525594, ERR2525595, ERR2525596, ERR2525597, 
ERR2525598, ERR2525599 and ERR252600. The accession 
numbers for all the reference Shigella and E. coli isolates used 
in the study are provided in the supplementary table.
INTRODUCTION
Shigella is the second leading cause of diarrhoeal death 
globally with the greatest disease burdens seen in low- and 
middle- income countries [1]. Approximately one- third of 
these deaths are in children under the age of 5 years, with 
infection potentially causing chronic health effects [1, 2]. 
Antimicrobial resistance (AMR) increasingly limits treat-
ment options, threatening to reverse hard won reductions in 
diarrhoeal mortality in high- burden areas [3]. Meanwhile, 
vaccines are still in development. There is therefore a need 
for effective public health solutions.
The increasing prevalence of fluoroquinolone- resistant (FQR) 
strains and limited, widely effective alternatives to this first- 
line treatment, has led to these strains being included on 
the WHO global priority pathogens list [4]. Resistance can 
be acquired de novo through a double mutation in the gyrA 
gene (amino acids 83 and 87) of the quinolone resistance 
determining region (QRDR), with a third mutation in the 
parC gene (AA80) ameliorating the fitness cost [5]. Resistance 
can also be acquired through horizontal transmission of FQR 
genes [5].
Shigella is reported as a leading cause of diarrhoea among 
hospitalized children in Malawi, but there is little information 
on the circulating strains [6]. Whole genome sequence analysis 
(WGSA) has been successfully applied to investigate Shigella 
epidemiology and AMR determinants, and can greatly aid 
in disease control in high- burden areas, such as Malawi [7]. 
Here, we have applied WGSA to characterize Shigella strains 
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baseline information for public health interventions including 
antibiotic treatment and deployment of Shigella vaccines, the 
development of which is a WHO priority [8].
The study
All biochemically confirmed shigellae collected during a rota-
virus vaccine evaluation programme between 2012 and 2015, 
isolated from faecal samples collected from children under 
the age of 5 years and hospitalized with acute gastroenteritis 
at the Queen Elizabeth Central Hospital, Blantyre, Malawi, 
were subjected to WGS (Supplementary methods) [9]. Species 
were confirmed with a maximum- likelihood phylogeny of 
the Shigella/Escherichia coli clade, generated from a core 
single nucleotide polymorphism (SNP) alignment (40 075 
SNPs) using quality trimmed reads mapped to a complete 
reference genome (Supplementary table). Only those genomi-
cally confirmed as Shigella or E. coli (8/10) were included in 
the study. All Shigella isolates were serotyped in silico with 
ShigaTyper (v1.0.6, https:// github. com/ CFSAN- Biostatistics/ 
shigatyper).
From our eight isolates, four Shigella serotypes were identi-
fied: two S. flexneri 3a (Sf3a, Phylogroup 2), one S. flexneri 
4av (Sf4av, Phylogroup 7), two S. flexneri 6 (Sf6) and one S. 
boydii 2 (Sb, Clade 3). Two isolates were of E. coli (Fig. 1a). The 
lack of Shigella sonnei isolates in our collection was expected 
as S. sonnei, though highly prevalent globally, is typically 
associated with high- income nations and industrialization 
[10]. Prevalence of S. boydii in Africa is thought to be low, 
isolated in 5.7 % of cases from a multi- national study [11]. 
However, detection with our small sample size would still be 
likely by chance (binomial test P=0.375) and may not be due 
to higher prevalence in Malawi. The strain diversity indicates 
that several, distinct strains circulate in Malawi; further char-
acterization is needed to aid effective vaccine development 
for the region.
Identification of E. coli among the samples is probably due 
to the close relatedness between the two species. Shigella is a 
specialized pathovar of E. coli, sharing a disease phenotype 
with enteroinvasive E. coli (EIEC), which is highly adapted 
to humans [12]. To determine whether the E. coli isolates 
were EIEC we looked for the presence of the mxi- spa locus, 
found on the large virulence plasmid (pINV). This locus 
encodes a Type 3 Secretion System and secreted effector 
proteins which produce the distinctive invasive disease 
phenotype [12, 13]. Contiguous sequences (contigs) from 
quality- assessed isolate draft genomes, assembled using 
Unicycler (v0.4.7) [14], were compared against a reference 
EIEC pINV to identify locus presence (Supplementary 
table). Using this approach, one E. coli isolate was identi-
fied as EIEC (99 % identity and 100 % coverage with the 
mxi- spa locus).
As resistance is a growing hinderance to effective treatment, 
we determined genotypic AMR profiles for each isolate 
using starAMR (v0.5.1; https:// github. com/ phac- nml/ 
staramr; Supplementary methods). All Shigella isolates were 
predicted to be multi- drug- resistant (MDR), carrying genes 
conferring resistance to three or more drug classes, demon-
strating MDR Shigella circulate in Malawi (Table 1). While 
overall resistance was high, we observed limited diversity 
in AMR genes and predicted resistance profiles; 13 genes 
encoded resistance to seven antimicrobial classes (Fig. 1b, 
Table  1). This suggests that there are treatments which 
remain effective in Malawi, such as azithromycin, though 
this would need to be confirmed in a larger study and may 
change with mass drug administration programmes.
Mobile genetic elements (MGEs) are important drivers of 
AMR dissemination, so we explored the genetic context of 
our AMR genes to look for evidence of them being within 
MGEs [15]. Resistance contigs from two isolates were 
identified as likely plasmid contigs, also using starAMR 
(Supplementary methods): one Sf3a isolate (22204_7#81) 
carried an MDR IncQ1 plasmid, and the Sf4av isolate 
carried a tet(A) encoding IncFIB(K) plasmid (Table 1). This 
contig was probably part of a MDR plasmid in combination 
with two other contigs, discussed below (Fig. 2). Another 
MDR contig had a read depth 5.29- fold higher than the 
chromosomal contigs, providing possible evidence of being 
part a multi- copy plasmid (Table 1). The same AMR gene 
profile (aph(3′′)- Ib, aph(6)- Id and sul2) was identified in 
contigs from multiple isolates (22204_7#74, 22204_7#78 
and 22204_7#79) across distinct phylogroups (Sb2 clade 3, 
Sf4av Phylogroup 7 and Sf6 respectively), possibly indicating 
an MGE (Fig. 1, Table 1). A comparison of these contigs 
showed that they had similarity (≥99 % sequence identity) 
to only the AMR gene- encoding region (2620–3184bp) 
(Supplementary methods). In one case (Sb2), however, 
this was the entire contig. The limited similarity across the 
Impact Statement
Antimicrobial resistance is a growing threat to our ability 
to treat bacterial infections. Multidrug resistance is wide-
spread among Shigella, a leading cause of diarrhoeal 
death globally. The greatest disease burden from shigel-
losis is on those living in low- and middle- income nations 
in sub- Saharan Arica and Asia. Emerging resistance to 
fluoroquinolone, the recommended first- line treatment, 
has been identified in Asia but is probably being missed 
in understudied regions. This study characterizes eight 
shigellae from Malawi, an area where Shigella has been 
understudied, looking, in particular, at antimicrobial 
resistance. All the isolates were found to be multidrug 
resistant, with one isolate probably resistant to fluoro-
quinolones. This fluoroquinolone resistance element was 
found to be carried on a plasmid conferring resistance 
to several other antimicrobials, indicating a probable 
threat of dissemination of multidrug resistance in the 
region. This study highlights the importance of studying 
all high disease burden regions, to ensure ongoing effec-
tive treatment of diarrhoeal diseases.
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Fig. 1. Maximum- likelihood phylogeny of eight isolates from Malawi, contextualized among Escherichia coli and Shigella and highlighting 
some AMR profiles of interest. AMR profiles of interest are those of contiguous sequences which are multi- drug- resistant and shared 
across multiple isolates, and in one isolate carries additional AMR genes including an FQR gene (qnrS1). They are indicated by columns 
to the right of the tree (a) and by coloured bars in the AMR profile chart (b). (a) Columns to the right of the phylogeny indicate, from left to 
right, species, study isolate and AMR profiles of interest. GTR+G substitution model, 1000 bootstrap validation and mid- point rooted. *S. 
boydii clade 3, ^S. flexneri phylogroup 2, γS. flexneri phylogroup 7. All bootstrap values for internal nodes with support <900 are displayed. 
Bar, SNPs per site. (b) Intersection of individual AMR genes by isolate and AMR gene profile by contig.
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whole contigs, and the presence of insertion sequences and 
transposase genes surrounding the AMR gene- encoding 
region in the largest of these contigs (Sf4av), suggests that 
these genes are more likely to have been spread via transpo-
sition than carriage on plasmids (Fig. 2b). One AMR gene 
(blaTEM- 1B) was identified as being carried within a Tn2 
transposon (Fig. 2b). Together, our data support a role for 
MGEs in the spread of MDR Shigella in Malawi.
To predict FQR, we looked for the presence of either point 
mutations in the QRDR, or FQR- associated genes. Point 
mutations were identified by comparing the gyrA and parC 
amino acid sequences across all isolates, with amino acid 
identity at resistance- associated sites confirmed as expected 
based on the literature. One isolate (Sf4av) was predicted to 
be FQR, due to the presence of qnrS1 (Table 1). A mutation 
at parC R91Q was also identified, but the same variation 
was present in all isolates, E. coli and Shigella, and prob-
ably represents natural variation rather than a resistance 
adaptation. Unfortunately, phenotype data were unavailable 
to confirm these findings.
Detection of qnrS1 indicates acquirable FQR is present 
among Shigella in Malawi. As this gene is typically carried 
on a plasmid, a blast comparison of the qnrS1- containing 
contig (17 334 bases) against the NCBI nt database was 
performed [5]. Three top equivocal hits against S. flexneri 
plasmids (KY848295.1, CP024474.1, LR213454.1) were 
found (e- score=0.0, query sequence coverage and identity 
≥99.9 %), suggesting that this gene might be carried on a 
related plasmid. To investigate this possibility, the contigs 
of the draft genome were compared (by blast) to iden-
tify other contigs which probably belong to this plasmid, 
and three contigs were identified in total (e- value=0.0) 
(Supplementary methods). Together, the contigs showed 
high sequence similarity and sequence coverage against all 
three plasmids, which were themselves highly similar to 
each other (Fig. 2). It is likely that our isolate was carrying 
a plasmid very similar to these other previously identi-
fied plasmids. This is supported by the isolate sequence 
read mapping coverage (mean depth=53 reads) to the S. 
flexneri 1c strain AUSMDU00008355 plasmid 3 (LR213454) 
(Supplementary methods). The probable presence of an 
qnrS1- carrying plasmid means a high risk of widespread 
FQR in Malawi and neighbouring regions; further study 
into the prevalence and nature of FQR in the region is 
needed.
All four of these highly similar plasmids are MDR, encoding 
sul2, aph(3′′)- Ib, aph(6)- Id, blaTEM- 1B and qnrS1 genes. 
Our isolate and one other also carry an additional resist-
ance gene tet(A) (Fig. 2). Each was identified in a different 
S. flexneri serotype (1c, Y, 7b and 4av), suggesting the 
dissemination of this MDR plasmid across multiple line-
ages. They were also identified across multiple continents 
[specifically in Australia, China, America (unpublished) 
and Malawi] [16–18]. This suggests the plasmid has been 
Table 1. AMR genotypic and predicted phenotypic profiles of Malawian Shigella isolates by contiguous sequence




2798 aph(3′′)- Ib, aph(6)- Id, sul2 Aminoglycoside, sulfonamide
2353 dfrA7 Trimethoprim
1831 blaTEM- 1B Aminopenicillin
22204_7#78
(S. flexneri 4av)
48 082 tet(A) Tetracycline




34 138 tet(A), sul1, dfrA7, catA1 Tetracycline, sulfonamide, trimethoprim, chloramphenicol
6200 aph(3′′)- Ib, aph(6)- Id, sul2 Aminoglycoside, sulfonamide
22204_7#80
(S. flexneri 6)
25 733 tet(A), sul1, dfrA7, catA1 Tetracycline, sulfonamide, trimethoprim, chloramphenicol
6200 aph(3′′)- Ib, sul2 Aminoglycoside, sulfonamide
22204_7#81
(S. flexneri 3a)
11 392† dfrA14, sul2, tet(A) Trimethoprim, sulfonamide, tetracycline
22204_7#82
(S. flexneri 3a)
45 377 tet(B) Tetracycline
8773 aadA1, blaOXA-1, catA1 Aminoglycoside, aminopenicillin, chloramphenicol
6790‡ aph(6)- Id, dfrA14, sul2 Aminoglycoside, trimethoprim, sulfonamide
*StarAMR identified IncFIB(K) plasmid.
†StarAMR identified MDR IncQ1 plasmid.
‡Possible multi- copy plasmid.
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successfully horizontally transmitted between strains and 
spread intercontinentally. It also provides evidence for 
an interaction between MDR Shigella globally and MDR 
Shigella in Malawi, though further research is needed to 
characterize this.
CONCLUSIONS
Together, the high proportion of MDR Shigella, the acquir-
able FQR and the MDR plasmids detected in this study 
show that, without intervention, controlling shigellosis in 
Malawi will be increasingly difficult, which will probably 
have global consequences. We highlight the importance of 
further research into the epidemiology of Shigella in the 
region to ensure effective disease control.
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